抑制心肌纤维化促进心肌再生治疗慢性心血管疾病  

Suppressing Myocardial Fibrosis to Promote Myocardial Regeneration as a Therapeutic Strategy for Chronic Cardiovascular Diseases

作　　者：米粟[1] 胡卓伟[1] 

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京100050

出　　处：《生理科学进展》2010年第5期352-358,共7页Progress in Physiological Sciences

基　　金：教育部长江学者特聘教授基金;科技部"973"计划项目(2006CB503808);国家自然科学基金(30973557)资助

摘　　要：以心肌肥厚、心肌细胞丢失和心肌组织纤维化为特征的心脏组织异常重构是各种慢性心血管疾病的核心病理改变。以组织异常重构,特别是以组织纤维化为靶点,利用小分子化合物如松弛素、KNK437,生物制剂如BCG、抗TLR2抗体或中药复方CFX等改变炎症性质,抑制甚至逆转纤维化不仅可以有效地改善心脏功能,还可为干细胞的动员和生长提供适宜环境,促进心肌再生,是治疗慢性心血管疾病的重要途径。Abnormal cardiovascular tissue remodeling characterized by myocardial hypertrophy,myocardial cell loss and myocardial fibrosis,are the primary pathological changes for multiple cardiovascular diseases.Targeting tissue remodeling using small molecules（e.g.relaxin,KNK437）,biological agents（e.g.BCG,anti-TLR2 antibody）,or herb medicine complex CFX and so on,can attenuate tissue fibrosis and improve cardiac functions.Therefore,regulating the property of inflammation and reversing tissue fibrosis should promote the formation of optimal tissue environments for stem cells mobilization and proliferation,which enhances the myocardial regeneration and is potential therapeutic strategy against chronic cardiovascular diseases.

关 键 词：慢性心血管疾病 心肌纤维化 心肌再生 炎症 干细胞治疗 

分 类 号：R542.23[医药卫生—心血管疾病] R967[医药卫生—内科学]